Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
C.NINE: Drill Rig Mobilization for the Wedge 10,000m Drill Program & Targeting New High Grade Copper Zone (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Alpha Tau Medical Ltd DRTS

Alternate Symbol(s):  DRTSW

Healthcare Biotechnology
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical... see more

Recent & Breaking News (NDAQ:DRTS)

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

GlobeNewswire May 11, 2023

Alpha Tau Medical to Present at Guggenheim Radiopharmaceuticals Day

GlobeNewswire May 3, 2023

Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial

GlobeNewswire April 3, 2023

Alpha Tau Medical to Present at Jefferies Radiopharma Innovation Summit

GlobeNewswire March 29, 2023

Alpha Tau Medical Confirms No Direct Exposure to Silicon Valley Bank

GlobeNewswire March 12, 2023

Alpha Tau Medical Announces Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 9, 2023

Alpha Tau Announces Alpha DaRT(TM) Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

GlobeNewswire March 8, 2023

Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters

GlobeNewswire March 3, 2023

Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases

GlobeNewswire March 1, 2023

Alpha Tau to Participate in Citi's 2023 Healthcare Services, Medtech, Tools & HCIT Conference

GlobeNewswire February 21, 2023

Alpha Tau to Present at Biotech Showcase and Participate in LifeSci Advisors Corporate Access Event During J.P. Morgan Healthcare Conference in San Francisco in January 2023

GlobeNewswire December 13, 2022

Alpha Tau Medical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 22, 2022

Alpha Tau to Present at Upcoming November Investor Conferences

GlobeNewswire November 9, 2022

Alpha Tau Announces Multiple Corporate Updates Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology

GlobeNewswire October 21, 2022

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Alpha DaRT Treatment and Standard-of-Care Immunotherapy, Chemotherapy and Anti-Angiogenic Therapy

GlobeNewswire September 8, 2022

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

GlobeNewswire September 1, 2022

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

GlobeNewswire August 30, 2022

Alpha Tau Medical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 25, 2022

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

GlobeNewswire August 22, 2022

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

GlobeNewswire July 5, 2022

Podcasts